EKF Diagnostics is a global medical diagnostics business with specialisms in point-of-care testing, central laboratory tests, enzyme manufacturing and the provision of contract manufacturing services to the healthcare industry.
EKF is listed on the London Stock Exchange's AIM market.
EKF's Point-of-Care heritage dates back to the development of glucose sensor technology in the 1990s. Since then our portfolio has broadened to include lactate, HbA1c and ketone testing.
EKF Diagnostics is also a manufacturer of Central Laboratory products including Stanbio Chemistry reagents, benchtop analyzers, rapid tests and centrifuges. Our chemistry reagents can be used on the majority of analyzers found in hospital laboratories around the world.
EKF Life Sciences has a long and successful reputation for delivering enzymes and contracted bio-products. The recently expanded production capacity at our manufacturing sites in the USA provides EKF Life Sciences with facilities to suit long-standing, high volume enzyme customers, as well as provide the flexibility needed for start-ups looking for tailored solutions.
EKF is listed on the London Stock Exchange's AIM market.
EKF's Point-of-Care heritage dates back to the development of glucose sensor technology in the 1990s. Since then our portfolio has broadened to include lactate, HbA1c and ketone testing.
EKF Diagnostics is also a manufacturer of Central Laboratory products including Stanbio Chemistry reagents, benchtop analyzers, rapid tests and centrifuges. Our chemistry reagents can be used on the majority of analyzers found in hospital laboratories around the world.
EKF Life Sciences has a long and successful reputation for delivering enzymes and contracted bio-products. The recently expanded production capacity at our manufacturing sites in the USA provides EKF Life Sciences with facilities to suit long-standing, high volume enzyme customers, as well as provide the flexibility needed for start-ups looking for tailored solutions.
Location: United Kingdom, Wales, Penarth
Employees: 201-500
Phone: +44 29 2071 0570
Founded date: 1990
Investors 1
| Date | Name | Website |
| - | H2O Ventur... | h2ovp.com |
Mentions in press and media 18
| Date | Title | Description |
| 31.01.2022 | EKF Diagnostics : Non-executive Directorate Change | EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces the appointment of Jenny Winter as Non-executive Director ("NED"), effective on 1 February 2022. At the same time Carl Contadini, Non-execut... |
| 23.11.2021 | EKF Diagnostics : Directorate Change | EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces the appointment of Marc Davies as Chief Financial Officer ("CFO"). Marc will join the Board as CFO on 1 January 2022, and will succeed Richa... |
| 11.11.2021 | EKF Diagnostics acquires ADL Health molecular diagnostic testing laboratory | EKF Diagnostics, the global in vitro diagnostics company, announces that it has acquired Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based PCR-focused testing laboratory certified under the Clinical Laboratory Impro... |
| 08.11.2021 | Director/PDMR Shareholding | EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that it has been notified that on 8 November 2021 Julian Baines, Non-Executive Deputy Chairman, sold a total of 250,000 ordinary shares of 1 pence eac... |
| 26.10.2021 | Dividend confirmation | EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that the Board has confirmed a cash dividend of 1.1p per ordinary share which will be paid on 1 December 2021. The dividend timetable dates are below:... |
| 12.10.2021 | EKF Diagnostics : Completion of acquisition, Admission & TVR Update | Capitalised terms in this announcement carry the same meaning as in the RNS of 28 September 2021, unless otherwise stated EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that, further to the announc... |
| 05.10.2021 | EKF Diagnostics : PDMR/ PCA Dealings | EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that the Board of EKF has been informed that on Friday 1 October, 2021, certain funds connected to Christopher Mills, Non-executive Chairman, sold a t... |
| 28.09.2021 | EKF Diagnostics : Acquisition of US based Advanced Diagnostic Laboratory LLC | All-share initial payment for earnings enhancing, cash generative acquisition New testing capacity complements test kit manufacturing and point-of-care diagnostic instrument business EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed p... |
| 15.09.2021 | EKF Diagnostics : to showcase new handheld β-ketone and glucose analyzer at AACC 2021 | First live viewing of EKF's STAT-Site® WB analyzer for reliable and efficient dual analyte measurement from whole blood in seconds EKF Diagnostics, the global in vitro diagnostics company, announces that it will be demonstrating its new STA... |
| 16.06.2021 | EKF DIAGNOSTICS HOLDINGS PLC EKF Diagnostics : Change of Adviser | EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces the appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and broker, N+1... |
Show more